Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.29
- Piotroski Score 7.00
- Grade Buy
- Symbol (CPRX)
- Company Catalyst Pharmaceuticals, Inc.
- Price $19.57
- Changes Percentage (-1.9%)
- Change -$0.38
- Day Low $19.53
- Day High $20.01
- Year High $21.67
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $19.00
- High Stock Price Target $24.00
- Low Stock Price Target $15.50
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.56
- Trailing P/E Ratio 27.89
- Forward P/E Ratio 27.89
- P/E Growth 27.89
- Net Income $71.41 M
Income Statement
Quarterly
Annual
Latest News of CPRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ...
Catalyst Pharmaceuticals Inc focuses on developing therapies for rare diseases. Insiders have sold 190,000 shares over the past year, part of a trend with 14 sells and no buys. The stock is trading at...
By Yahoo! Finance | 1 month ago
